JFK Communications served as Eisai’s PR agency supporting their emerging oncology portfolio. This work included support for in-line products such as, Ontak, Targretin, Panretin and Aloxi. This work also included support for eribulin (Halaven) for the treatment of metastatic breast cancer.
JFK provided core corporate oncology and product public relations services including:
- Data communications
- KOL development; media training
- Media relations
- Clinical trial recruitment
- Medical meeting support
- Patient advocacy relations
- Global regulatory milestone announcements
- Oncology drugs advisory committee meetings
- Issues management
